Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Two's a Crowd: Versartis Raises $21 Million Series B, Cleaves Off Diabetes Asset to Form Diartis Pharma

This article was originally published in The Pink Sheet Daily

Executive Summary

Citing different financial needs, Versartis' backers have created Diartis to take its GLP-1 molecule to proof of concept, while Versartis focuses on human growth hormone.

You may also be interested in...



Financings of the Fortnight Wants To Spin You Right 'Round, And Out

Recently public Akebia is just one of the many biotechs making a case for spin-outs driven by economic needs. Also, Sangamo, Ataxion, Galmed and SAGE tap the financing pool.

After Complex Sale, Amira Scientist And VC Team Up Again For Discovery Start-up

Versant Ventures is backing Inception Sciences, a new company led by former Amira chief scientist Peppi Prasit that aims to spin out multiple programs into separate companies, a new model gaining traction in the biotech world.

After Complex Sale, Amira Scientist And VC Team Up Again For Discovery Start-up

Versant Ventures is backing Inception Sciences, a new company led by former Amira chief scientist Peppi Prasit that aims to spin out multiple programs into separate companies, a new model gaining traction in the biotech world.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071839

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel